Tags : Novel Brain Cancer Drug

Pharma

Moleculin Reports Dosing of Novel Brain Cancer Drug WP1066 in

Shots: The P-I trial is assessing WP1066 in 15 patients with relapsed brain tumor for 6 to 8mos, testing its safety and tolerability in patients at MD Anderson Cancer Centre WP1066 a novel STAT3i (originated from active ingredient in propolis) has shown promising results in animal studies inhibiting tumor growth with improvement in survival Mayo […]Read More